The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Space The AMOC moves closer to collapse, scientists create artificial neurons, the "Iliad" is found inside and Egyptian mummy, and researchers search for treatments for brain-eating amoebas Artificial ...

GameSpot may get a commission from retail offers. When Barbarian and Weapons director Zach Cregger signed on to helm the next Resident Evil movie, it was described as "a revamp that will take the ...

March 9 (Reuters) - Xenon Pharmaceuticals (XENE.O), opens new tab said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction ‌in focal onset ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Xenon Pharmaceuticals Inc. XENE-Q stock soared Monday after the Canadian drug developer reported better-than-expected results from a late-stage human trial for its epilepsy treatment. Burnaby, ...

Any lingering disappointment in the delay for Xenon Pharmaceuticals Inc.’s readout of the phase III X-Tole2 study testing azetukalner in focal onset seizures (FOS) appeared thoroughly extinguished as ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...